技术资料
-
Baksh D et al. (NOV 2005) Blood 106 9 3012--9Soluble factor cross-talk between human bone marrow-derived hematopoietic and mesenchymal cells enhances in vitro CFU-F and CFU-O growth and reveals heterogeneity in the mesenchymal progenitor cell compartment.
The homeostatic adult bone marrow (BM) is a complex tissue wherein physical and biochemical interactions serve to maintain a balance between the hematopoietic and nonhematopoietic compartments. To focus on soluble factor interactions occurring between mesenchymal and hematopoietic cells,a serum-free adhesion-independent culture system was developed that allows manipulation of the growth of both mesenchymal and hematopoietic human BM-derived progenitors and the balance between these compartments. Factorial experiments demonstrated a role for stem cell factor (SCF) and interleukin 3 (IL-3) in the concomitant growth of hematopoietic (CD45+) and nonhematopoietic (CD45-) cells,as well as their derivatives. Kinetic tracking of IL-3alpha receptor (CD123) and SCF receptor (CD117) expression on a sorted CD45- cell population revealed the emergence of CD45-CD123+ cells capable of osteogenesis. Of the total fibroblast colony-forming units (CFU-Fs) and osteoblast colony-forming units (CFU-O),approximately 24% of CFU-Fs and about 22% of CFU-Os were recovered from this population. Cell-sorting experiments demonstrated that the CD45+ cell population secreted soluble factors that positively affect the survival and proliferation of CFU-Fs and CFU-Os generated from the CD45- cells. Together,our results provide insight into the intercellular cytokine network between hematopoietic and mesenchymal cells and provide a strategy to mutually culture both mesenchymal and hematopoietic cells in a defined scalable bioprocess. View Publication -
Fassnacht M et al. (AUG 2005) Clinical cancer research : an official journal of the American Association for Cancer Research 11 15 5566--71Induction of CD4(+) and CD8(+) T-cell responses to the human stromal antigen, fibroblast activation protein: implication for cancer immunotherapy.
PURPOSE: The propensity of tumor cells to escape immune elimination could limit,if not defeat,the long-term benefits of effective immunotherapeutic protocols. Immunologic targeting of tumor stroma could significantly reduce the ability of tumors to evade immune elimination. Murine studies have shown that inducing immunity against angiogenesis-associated products engenders potent antitumor immunity without significant pathology. It is,however,not known whether T cells corresponding to stromal products are present in humans. In this study,we describe a method to screen for human stromal products that have not triggered significant tolerance and could therefore serve as candidate antigens for cancer immunotherapy. EXPERIMENTAL DESIGN: To identify candidates for human stromal antigens,we used an in vitro-screening method to determine whether dendritic cells transfected with mRNA encoding products,which are overexpressed in the tumor stroma,are capable of stimulating cytotoxic CD8(+) (CTL) responses from human peripheral blood mononuclear cells. RESULTS: CTL responses could be consistently generated against fibroblast activation protein (FAP) but not against matrix metalloproteinase-9 (MMP-9) or MMP-14. To enhance the immunogenicity of the mRNA-translated FAP product,a lysosomal targeting signal derived from lysosome-associated membrane protein-1 (LAMP-1) was fused to the COOH terminus of FAP to redirect the translated product into the class II presentation pathway. Dendritic cells transfected with mRNA encoding the FAP-LAMP fusion product stimulated enhanced CD4(+) and CD8(+) T-cell responses. CONCLUSION: This study identifies FAP,a protease preferentially expressed in tumor-associated fibroblasts,as a candidate human stromal antigen to target in the setting of cancer immunotherapy,and shows that differential expression of stromal products is not a sufficient criteria to indicate its immunogenicity in a vaccination setting. View Publication -
Rohde E et al. (FEB 2006) Stem cells (Dayton,Ohio) 24 2 357--67Blood monocytes mimic endothelial progenitor cells.
The generation of endothelial progenitor cells (EPCs) from blood monocytes has been propagated as a novel approach in the diagnosis and treatment of cardiovascular diseases. Low-density lipoprotein (LDL) uptake and lectin binding together with endothelial marker expression are commonly used to define these EPCs. Considerable controversy exists regarding their nature,in particular,because myelomonocytic cells share several properties with endothelial cells (ECs). This study was performed to elucidate whether the commonly used endothelial marker determination is sufficient to distinguish supposed EPCs from monocytes. We measured endothelial,hematopoietic,and progenitor cell marker expression of monocytes before and after angiogenic culture by fluorescence microscopy,flow cytometry,and real-time reverse transcription-polymerase chain reaction. The function of primary monocytes and monocyte-derived supposed EPCs was investigated during vascular network formation and EC colony-forming unit (CFU-EC) development. Monocytes cultured for 4 to 6 days under angiogenic conditions lost CD14/CD45 and displayed a commonly accepted EPC phenotype,including LDL uptake and lectin binding,CD31/CD105/CD144 reactivity,and formation of cord-like structures. Strikingly,primary monocytes already expressed most tested endothelial genes and proteins at even higher levels than their supposed EPC progeny. Neither fresh nor cultured monocytes formed vascular networks,but CFU-EC formation was strictly dependent on monocyte presence. LDL uptake,lectin binding,and CD31/CD105/CD144 expression are inherent features of monocytes,making them phenotypically indistinguishable from putative EPCs. Consequently,monocytes and their progeny can phenotypically mimic EPCs in various experimental models. View Publication -
Alexanian AR (NOV 2005) Experimental cell research 310 2 383--91Neural stem cells induce bone-marrow-derived mesenchymal stem cells to generate neural stem-like cells via juxtacrine and paracrine interactions.
Several recent reports suggest that there is far more plasticity that previously believed in the developmental potential of bone-marrow-derived cells (BMCs) that can be induced by extracellular developmental signals of other lineages whose nature is still largely unknown. In this study,we demonstrate that bone-marrow-derived mesenchymal stem cells (MSCs) co-cultured with mouse proliferating or fixed (by paraformaldehyde or methanol) neural stem cells (NSCs) generate neural stem cell-like cells with a higher expression of Sox-2 and nestin when grown in NS-A medium supplemented with N2,NSC conditioned medium (NSCcm) and bFGF. These neurally induced MSCs eventually differentiate into beta-III-tubulin and GFAP expressing cells with neuronal and glial morphology when grown an additional week in Neurobasal/B27 without bFGF. We conclude that juxtacrine interaction between NSCs and MSCs combined with soluble factors released from NSCs are important for generation of neural-like cells from bone-marrow-derived adherent MSCs. View Publication -
Arbab AS et al. (MAR 2006) Stem cells (Dayton,Ohio) 24 3 671--8Magnetic resonance imaging and confocal microscopy studies of magnetically labeled endothelial progenitor cells trafficking to sites of tumor angiogenesis.
UNLABELLED: AC133 cells,a subpopulation of CD34+ hematopoietic stem cells,can transform into endothelial cells that may integrate into the neovasculature of tumors or ischemic tissue. Most current imaging modalities do not allow monitoring of early migration and incorporation of endothelial progenitor cells (EPCs) into tumor neovasculature. The goals of this study were to use magnetic resonance imaging (MRI) to track the migration and incorporation of intravenously injected,magnetically labeled EPCs into the blood vessels in a rapidly growing flank tumor model and to determine whether the pattern of EPC incorporation is related to the time of injection or tumor size. MATERIALS AND METHODS: EPCs labeled with ferumoxide-protamine sulfate (FePro) complexes were injected into mice bearing xenografted glioma,and MRI was obtained at different stages of tumor development and size. RESULTS: Migration and incorporation of labeled EPCs into tumor neovasculature were detected as low signal intensity on MRI at the tumor periphery as early as 3 days after EPC administration in preformed tumors. However,low signal intensities were not observed in tumors implanted at the time of EPC administration until tumor size reached 1 cm at 12 to 14 days. Prussian blue staining showed iron-positive cells at the sites corresponding to low signal intensity on MRI. Confocal microscopy showed incorporation into the neovasculature,and immunohistochemistry clearly demonstrated the transformation of the administered EPCs into endothelial cells. CONCLUSION: MRI demonstrated the incorporation of FePro-labeled human CD34+/AC133+ EPCs into the neovasculature of implanted flank tumors. View Publication -
Hu X et al. (JAN 2006) Blood 107 2 821--6Deletion of the core region of 5' HS2 of the mouse beta-globin locus control region reveals a distinct effect in comparison with human beta-globin transgenes.
The beta-globin locus control region (LCR) is a large DNA element that is required for high-level expression of beta-like globin genes from the endogenous mouse locus or in transgenic mice carrying the human beta-globin locus. The LCR encompasses 6 DNaseI hypersensitive sites (HSs) that bind transcription factors. These HSs each contain a core of a few hundred base pairs (bp) that has most of the functional activity and exhibits high interspecies sequence homology. Adjoining the cores are 500- to 1000-bp flanks" with weaker functional activity and lower interspecies homology. Studies of human beta-globin transgenes and of the endogenous murine locus show that deletion of an entire HS (core plus flanks) moderately suppresses expression. However View Publication -
Tang YL et al. (OCT 2005) Journal of the American College of Cardiology 46 7 1339--50Improved graft mesenchymal stem cell survival in ischemic heart with a hypoxia-regulated heme oxygenase-1 vector.
OBJECTIVES: The goal of this study was to modify mesenchymal stem cells (MSCs) cells with a hypoxia-regulated heme oxygenase-1 (HO-1) plasmid to enhance the survival of MSCs in acute myocardial infarction (MI) heart. BACKGROUND: Although stem cells are being tested clinically for cardiac repair,graft cells die in the ischemic heart because of the effects of hypoxia/reoxygenation,inflammatory cytokines,and proapoptotic factors. Heme oxygenase-1 is a key component in inhibiting most of these factors. METHODS: Mesenchymal stem cells from bone marrow were transfected with either HO-1 or LacZ plasmids. Cell apoptosis was assayed in vitro after hypoxia-reoxygen treatment. In vivo,1 x 10(6) of male MSC(HO-1),MSC(LacZ),MSCs,or medium was injected into mouse hearts 1 h after MI (n = 16/group). Cell survival was assessed in a gender-mismatched transplantation model. Apoptosis,left ventricular remodeling,and cardiac function were tested in a gender-matched model. RESULTS: In the ischemic myocardium,the MSC(HO-1) group had greater expression of HO-1 and a 2-fold reduction in the number of terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate in situ nick end labeling-positive cells compared with the MSC(LacZ) group. At seven days after implantation,the survival MSC(HO-1) was five-fold greater than the MSC(LacZ) group; MSC(HO-1) also attenuated left ventricular remodeling and enhanced the functional recovery of infarcted hearts two weeks after MI. CONCLUSIONS: A hypoxia-regulated HO-1 vector modification of MSCs enhances the tolerance of engrafted MSCs to hypoxia-reoxygen injury in vitro and improves their viability in ischemic hearts. This demonstration is the first showing that a physiologically inducible vector expressing of HO-1 genes improves the survival of stem cells in myocardial ischemia. View Publication -
Yu H et al. (FEB 2006) Blood 107 3 1200--6Hematopoietic stem cell exhaustion impacted by p18 INK4C and p21 Cip1/Waf1 in opposite manners.
Transplantation-associated stress can compromise the hematopoietic potential of hematopoietic stem cells (HSCs). As a consequence,HSCs may undergo exhaustion" in serial transplant recipients View Publication -
Hoebeke I et al. (APR 2006) Blood 107 7 2879--81Overexpression of HES-1 is not sufficient to impose T-cell differentiation on human hematopoietic stem cells.
By retroviral overexpression of the Notch-1 intracellular domain (ICN) in human CD34+ hematopoietic stem cells (HSCs),we have shown previously that Notch-1 signaling promotes the T-cell fate and inhibits the monocyte and B-cell fate in several in vitro and in vivo differentiation assays. Here,we investigated whether the effects of constitutively active Notch-1 can be mimicked by overexpression of its downstream target gene HES1. Upon HES-1 retroviral transduction,human CD34+ stem cells had a different outcome in the differentiation assays as compared to ICN-transduced cells. Although HES-1 induced a partial block in B-cell development,it did not inhibit monocyte development and did not promote T/NK-cell-lineage differentiation. On the contrary,a higher percentage of HES-1-transduced stem cells remained CD34+. These experiments indicate that HES-1 alone is not able to substitute for Notch-1 signaling to induce T-cell differentiation of human CD34+ hematopoietic stem cells. View Publication -
Joachims ML et al. (FEB 2006) Journal of immunology (Baltimore,Md. : 1950) 176 3 1543--52Human alpha beta and gamma delta thymocyte development: TCR gene rearrangements, intracellular TCR beta expression, and gamma delta developmental potential--differences between men and mice.
To evaluate the role of the TCR in the alphabeta/gammadelta lineage choice during human thymocyte development,molecular analyses of the TCRbeta locus in gammadelta cells and the TCRgamma and delta loci in alphabeta cells were undertaken. TCRbeta variable gene segments remained largely in germline configuration in gammadelta cells,indicating that commitment to the gammadelta lineage occurred before complete TCRbeta rearrangements in most cases. The few TCRbeta rearrangements detected were primarily out-of-frame,suggesting that productive TCRbeta rearrangements diverted cells away from the gammadelta lineage. In contrast,in alphabeta cells,the TCRgamma locus was almost completely rearranged with a random productivity profile; the TCRdelta locus contained primarily nonproductive rearrangements. Productive gamma rearrangements were,however,depleted compared with preselected cells. Productive TCRgamma and delta rearrangements rarely occurred in the same cell,suggesting that alphabeta cells developed from cells unable to produce a functional gammadelta TCR. Intracellular TCRbeta expression correlated with the up-regulation of CD4 and concomitant down-regulation of CD34,and plateaued at the early double positive stage. Surprisingly,however,some early double positive thymocytes retained gammadelta potential in culture. We present a model for human thymopoiesis which includes gammadelta development as a default pathway,an instructional role for the TCR in the alphabeta/gammadelta lineage choice,and a prolonged developmental window for beta selection and gammadelta lineage commitment. Aspects that differ from the mouse are the status of TCR gene rearrangements at the nonexpressed loci,the timing of beta selection,and maintenance of gammadelta potential through the early double positive stage of development. View Publication -
Mandal M et al. ( 2006) Oral oncology 42 4 430--439The Akt inhibitor KP372-1 inhibits proliferation and induces apoptosis and anoikis in squamous cell carcinoma of the head and neck.
Therapies that target signaling pathways critical to the pathogenesis and progression of squamous cell carcinoma of the head and neck (HNSCC) are needed. One such target,phosphatidylinositol 3-kinase,and its downstream target serine/threonine kinase,Akt,are up-regulated in HNSCC. Targeted therapy could consist of inhibitors of these kinases or,alternatively,of inhibitors of the pathways that they regulate. To explore the effect of Akt inhibition on the growth and survival of HNSCC tumors,we evaluated the effect of a novel Akt inhibitor,KP372-1,on the growth,survival,and sensitivity to anoikis of HNSCC cell lines in culture. Using Western blotting of head and neck cancer cell lines and squamous mucosa and carcinoma specimens,we found that Akt was highly phosphorylated in head and neck cancer cell lines and human head and neck squamous carcinoma specimens. Treatment of HNSCC cell lines with KP372-1 blocked the activation of Akt,inhibited head and neck cancer cell proliferation,and induced apoptosis and anoikis in several HNSCC cell lines. Furthermore,KP372-1 decreased the phosphorylation of the S6 ribosomal (Ser240/244) protein,which is a downstream target of Akt. Taken together,these findings indicate that KP372-1 may be a useful therapeutic agent for HNSCC and should be further evaluated in preclinical models of HNSCC. View Publication -
Pyle AD et al. (MAR 2006) Nature biotechnology 24 3 344--50Neurotrophins mediate human embryonic stem cell survival.
Growth of human embryonic stem (hES) cells as a pluripotent population requires a balance between survival,proliferation and self-renewal signals. Here we demonstrate that hES cells express receptors of the tropomyosin-related kinase (TRK) family,which mediate antiapoptotic signals. We show that three TRK ligands,brain-derived neurotrophic factor,neurotrophin 3 and neurotrophin 4,are survival factors for hES cells. Addition of neurotrophins to hES cell cultures effects a 36-fold improvement in their clonal survival. hES cell cultures maintained in medium containing neurotrophins remain diploid and retain full developmental potency. In the presence of neurotrophins,TRK receptors in hES cells are phosphorylated; TRK receptor inhibition leads to hES cell apoptosis. The survival activity of neurotrophins in hES cells is mediated by the phosphatidylinositol-3-kinase pathway but not the mitogen-activated protein kinase pathway. Neurotrophins improve hES cell survival and may facilitate their manipulation and the development of high-throughput screens to identify factors responsible for hES cell differentiation. View Publication
过滤器
筛选结果
产品类型
- 仪器及软件
Show More
Show Less
研究领域
- HIV 70 项目
- HLA 52 项目
- 上皮细胞生物学 269 项目
- 免疫 1012 项目
- 内皮细胞研究 1 项目
- 呼吸系统研究 48 项目
- 嵌合体 25 项目
- 干细胞生物学 2827 项目
- 感染性疾病(传染病) 7 项目
- 抗体制备 7 项目
- 新陈代谢 7 项目
- 杂交瘤制备 2 项目
- 疾病建模 248 项目
- 癌症 6 项目
- 神经科学 650 项目
- 移植研究 100 项目
- 类器官 178 项目
- 细胞外囊泡研究 10 项目
- 细胞治疗开发 18 项目
- 细胞疗法开发 113 项目
- 细胞系制备 191 项目
- 脐带血库 64 项目
- 血管生成细胞研究 1 项目
- 传染病 64 项目
- 内皮细胞生物学 7 项目
- 杂交瘤生成 14 项目
- 癌症研究 724 项目
- 血管生成细胞研究 51 项目
Show More
Show Less
产品系列
- ALDECOUNT 14 项目
- CellPore 11 项目
- CellShield 1 项目
- CellSTACK 1 项目
- DermaCult 1 项目
- EasyPick 1 项目
- ELISA 3 项目
- ES-Cult 78 项目
- Falcon 1 项目
- GloCell 1 项目
- GyneCult 1 项目
- HetaSep 1 项目
- Maestro 2 项目
- Matrigel 2 项目
- MegaCult 37 项目
- STEMprep 11 项目
- ALDEFLUOR 237 项目
- AggreWell 82 项目
- ArciTect 38 项目
- BloodStor 2 项目
- BrainPhys 84 项目
- CellAdhere 3 项目
- ClonaCell 107 项目
- CloneR 9 项目
- CryoStor 75 项目
- EC-Cult 1 项目
- EasySep 963 项目
- EpiCult 15 项目
- HemaTox 4 项目
- HepatiCult 32 项目
- Hypothermosol 1 项目
- ImmunoCult 39 项目
- IntestiCult 213 项目
- Lymphoprep 12 项目
- MammoCult 45 项目
- MesenCult 164 项目
- MethoCult 499 项目
- MyeloCult 65 项目
- MyoCult 10 项目
- NaïveCult 1 项目
- NeuroCult 373 项目
- NeuroFluor 3 项目
- PBS-MINI 8 项目
- PancreaCult 11 项目
- PneumaCult 119 项目
- RSeT 13 项目
- ReLeSR 10 项目
- RoboSep 43 项目
- RosetteSep 268 项目
- STEMdiff 193 项目
- STEMscript 1 项目
- STEMvision 7 项目
- SepMate 38 项目
- SmartDish 1 项目
- StemSpan 251 项目
- TeSR 1545 项目
- ThawSTAR 5 项目
- mFreSR 9 项目
- Highway1 7 项目
Show More
Show Less
细胞类型
- B 细胞 229 项目
- CD4+ 46 项目
- CD8+ 29 项目
- CHO细胞 15 项目
- HEK-293细胞(人胚肾293细胞) 2 项目
- NK 细胞 162 项目
- PSC衍生 37 项目
- T 细胞 441 项目
- 上皮细胞 143 项目
- 中胚层 5 项目
- 乳腺细胞 95 项目
- 先天性淋巴细胞 32 项目
- 全血 10 项目
- 其他子集 1 项目
- 其他细胞系 10 项目
- 内皮细胞 11 项目
- 内胚层 4 项目
- 前列腺细胞 18 项目
- 单个核细胞 93 项目
- 单核细胞 178 项目
- 多能干细胞 1986 项目
- 小胶质细胞 13 项目
- 巨噬细胞 42 项目
- 巨核细胞 10 项目
- 心肌细胞 21 项目
- 成骨细胞 10 项目
- 星形胶质细胞 14 项目
- 杂交瘤细胞 92 项目
- 树突状细胞(DCs) 118 项目
- 气道细胞 4 项目
- 淋巴细胞 73 项目
- 癌细胞及细胞系 149 项目
- 癌细胞和细胞系 1 项目
- 白细胞 24 项目
- 白细胞单采样本 13 项目
- 白血病/淋巴瘤细胞 14 项目
- 监管 1 项目
- 真皮细胞 3 项目
- 神经元 1 项目
- 神经干/祖细胞 465 项目
- 神经细胞 12 项目
- 粒细胞及其亚群 96 项目
- 红系细胞 12 项目
- 红细胞 13 项目
- 肌源干/祖细胞 11 项目
- 肝细胞 40 项目
- 肠道细胞 103 项目
- 肾细胞 4 项目
- 肿瘤细胞 27 项目
- 胰腺细胞 17 项目
- 脂肪细胞 6 项目
- 脑肿瘤干细胞 103 项目
- 血小板 4 项目
- 血浆 3 项目
- 血管生成细胞 1 项目
- 角质形成细胞 1 项目
- 调节性细胞 10 项目
- 软骨细胞 9 项目
- 造血干/祖细胞 968 项目
- 造血干祖细胞 6 项目
- 造血细胞 4 项目
- 间充质基质细胞 25 项目
- 间充质干/祖细胞 188 项目
- 间充质干祖细胞 1 项目
- 间充质细胞 3 项目
- 骨髓基质细胞 1 项目
- 骨髓间质细胞 2 项目
- 髓系细胞 135 项目
- 肾脏细胞 8 项目
- CD4+T细胞 100 项目
- CD8+T细胞 86 项目
- PSC衍生上皮细胞 39 项目
- PSC衍生中胚层 25 项目
- PSC衍生内皮细胞 20 项目
- PSC衍生内胚层 28 项目
- PSC衍生心肌细胞 26 项目
- PSC衍生神经细胞 130 项目
- PSC衍生肝细胞 18 项目
- PSC衍生造血干细胞 39 项目
- PSC衍生间充质细胞 27 项目
- 其他T细胞亚型 31 项目
- 呼吸道细胞 96 项目
- 多巴胺能神经元 6 项目
- 小鼠胚胎成纤维细胞 1 项目
- 浆细胞 17 项目
- 神经元 201 项目
- 调节性T细胞 59 项目
- 骨髓瘤 5 项目
Show More
Show Less

EasySep™小鼠TIL(CD45)正选试剂盒



沪公网安备31010102008431号